KREBSBIO vs MANGALAM: Stock Comparison

KREBS BIOCHEMICALS & IND vs MANGALAM DRUG & CHEMUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

KREBS BIOCHEMICALS & IND is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows faster revenue growth, while MANGALAM DRUG & CHEM shows a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 3; MANGALAM leads 4 of 9

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOMANGALAM

Valuation lens

What price are you paying?

Market CapContext only
₹121 Cr
₹48 Cr
P/E RatioSame reading
0x
P/B RatioSame reading
0x
EPSKREBSBIO has the higher reading
₹-1.15
₹-4.83
Book ValueContext only
₹65.11
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KREBSBIO is the larger company
₹121 Cr vs ₹48 Cr
EPS
KREBSBIO has higher earnings per share
₹-1.15 vs ₹-4.83
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -7.5%
Qtr Sales Growth
MANGALAM has stronger quarterly sales growth
0% vs -70.57%
Qtr Profit Growth
KREBSBIO has stronger quarterly profit growth
85.33% vs -1.13%
ROCE
MANGALAM has a higher ROCE
-15.52% vs -15.89%
Net Margin
MANGALAM has a higher net margin
-19.13% vs -71.35%
Operating Margin
MANGALAM has a higher operating margin
-13.66% vs -41.49%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOMANGALAM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOMANGALAM
Live Price₹55.95₹30.02
Day Change2.66%-0.92%
Volume5,83018,726
52-Week High₹82.49₹79.7
52-Week Low₹38.33₹22.8
Distance from 52W High-32.17%-62.33%

Valuation

MetricKREBSBIOMANGALAM
Market Cap₹121 Cr₹48 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹-1.15₹-4.83
Book Value₹65.11
Dividend Yield0%0%

Growth

MetricKREBSBIOMANGALAM
Revenue Growth (TTM YoY)11.6%-7.5%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-70.57%0%
Qtr Profit Growth85.33%-1.13%

Profitability & Leverage

MetricKREBSBIOMANGALAM
ROE-42.41%
ROCE-15.89%-15.52%
Net Margin-71.35%-19.13%
Operating Margin-41.49%-13.66%
Debt to Equity0.99x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKREBSBIOMANGALAM
Promoter Holding72.74%35.65%
FII Holding0.5%0.11% 0.21 pp
DII Holding0%0%
Public Holding26.76%64.24% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and MANGALAM DRUG & CHEM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.